Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial ...

The Pharma stocks are seeing big cuts in early trade. The Nifty Pharma Index is down over 1% and the BSE Healthcare Index too remains under pressure. Some of the big Nifty losers include the likes ...

For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the ...

For the second year in a row, the pharmaceutical industry has dipped further out of favor with patient groups around the world. The industry’s reputation surged during the COVID-19 pandemic ...

A fresh threat by US president Donald Trump on Monday that sector-specific tariffs on pharmaceuticals could be announced in the next two weeks has hammered the stocks of Indian drug-makers on ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump administration. This time it’s Gilead coming to the table with a ...

Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a ...

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

President Donald Trump signaled that he plans to announce new tariffs on pharmaceutical products imported to the United States “over the next two weeks.” Trump’s overriding tariff agenda has ...

Trump’s threat of pharma tariffs marks a fresh development in the president’s aggressive trade agenda. On Sunday, he threatened to impose 100% tariffs on foreign-made films.

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.25 per share a year ago.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...